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severity of complications like GVHD can be problematic. We have
assigned one full-time Nurse Practitioner (NP) to follow the allo-
geneic patients from day 80-100 to the end of the ﬁrst year after
transplantation. The LTFU programNP coordinates care with the
patient’s clinic physician and Physician Assistant (PA). An extensive
assessment is performed around the time the patient will be leaving
the transplant center. Baseline data and outcome tracking will
include incidence and severity of chronic graft vs. host disease,
infections, endocrine and nutritional disorders, quality of life, and
survival. Interesting trends have been noted and will be reported.
Information about assessment tools and outcomes will be shared.
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BK Virus is a polyomavirus that infects a large percentage of the
human population; however, clinically signiﬁcant infections de-
velop almost exclusively in immunocompromised patients. BK Vi-
rus is one of the viruses that may be associated with hemorrhagic
cystitis (HC) in bone marrow transplant (BMT) patients. Recently
at The Children’s Hospital in Denver there was concern that the
incidence of BK virus might be increasing in our BMT population.
Of the 307 patients transplanted from 1/94-8/06 (144 autologous
and 163 allogeneic), 60 developed HC, nine of these 60 in the last
year. BK virus was documented by urine PCR in 37; 6 had a
documented negative; and 17 had no documented BK testing.
Routine testing at our institution did not begin until 1999 and is
only done if a patient develops clinical HC. Evaluation of our data
currently does not support an increased incidence. It appears pa-
tients who are more severely immunocompromised, whether from
their disease or treatment regimen, were at greater risk for being
positive for BK virus-associated HC. An explanation of our in-
creased numbers is we are treating greater number of patients who
are more severely immunocompromised. In our population all
patients with a positive BK were 4 years or older. Although sex
does not appear to be a signiﬁcant risk factor, it appears clinically
boys had a higher morbidity than girls. Obstruction from clots that
resulted in pain & urine retention was the main complications boys
experienced. Treatment for BK virus is primarily related to symp-
tom management & includes aggressive hydration, pain & bladder
spasm treatment and transfusion support. Emotional support of
patients and family is critical. Cidoﬁvir has shown some efﬁcacy in
treatment of BK viruria. More severe cases have also received
bladder irrigation, prostaglandin instillation &/or hyperbaric oxy-
gen. Our institution is also exploring methods to prevent trans-
mission of the virus such as isolation and improved hand washing
techniques. Nursing management & support of patients and fam-
ilies is key to a successful outcome. This includes initiating a
diagnostic/treatment plan at the ﬁrst sign of HC, facilitating re-
search studies, providing explanations of the drugs and procedures
used to alleviate symptoms, monitoring labs and providing emo-
tional support. Since there are many unanswered questions and no
optimum treatment, we continue to need further research concern-
ing prevention & management of BK virus-associated HC.
421
IMPROVING YIELD FROM BLOOD CULTURES FOR TRANSPLANT PA-
TIENTS
Wood, J.M.1, Eilers, J.1, DeVetten, M.1, Freifeld, A.1 1Nebraska Med-
ical Center, Omaha, NE.
Treatment and disease related factors place hematopoietic stem
cell transplant (HSCT) patients at risk for life threatening infec-
tions. Multiple blood cultures are common in the attempt to
identify a causative organism, guide antimicrobial coverage, and
provide for optimum patient outcome. Historically there were
inconsistencies in the number of sets that were drawn and the
number of sites that were accessed for collecting the blood culture
specimens. The goal of this project was to develop an evidenced-
based protocol that would standardize practice for blood cultures
and improve the clinical usefulness of results. Our performance
improvement (PI) team worked with the transplant and infectious
disease physicians to develop the protocol for drawing blood cul-
tures. Staff were educated regarding the new policy and its ratio-
nale. Compliance with the protocol was monitored and variations
in practice were addressed with individual staff members. Three
months of data post protocol implementation (Time 2) were com-
pared with historical data (Time 1). During T1, 96 patients had
314 culture events; during T2, 85 patients had 293 culture events.
The average number of cultures per febrile patient during hospi-
talization in T1 was 4.5 sets, and each febrile patient was cultured
an average of 3.2 days during the hospital stay. In T2, each febrile
patient had an average of 7.4 culture sets drawn during the stay,
and was cultured an average of 3.4 days. In T1, 37% of the time
cultures were obtained from more than one site as compared to
89% in T2. Although the number of culture events did not change
signiﬁcantly, the protocol resulted in an increased number of
positive cultures and infections identiﬁed in febrile patients. This
project demonstrates how a nurse driven initiative can promote
evidenced-based practice change that has the potential to improve
patient outcomes.
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Infection is one of the leading causes of morbidity and mortality
in patients undergoing hematopoietic stem cell transplantation.
Increased risk of infection is associated with prolonged neutropenia
and delayed immune reconstitution which are common in recipi-
ents of unrelated donor cord blood or T-cell depleted adult grafts.
In the past, invasive fungal infections were frequent and more
difﬁcult to treat. Aspergillus is commonly seen in immunocompro-
mised patients and is challenging from a nursing care standpoint.
Patients with pulmonary involvement are often febrile with in-
creasing oxygen requirements in addition to having increased num-
bers of medication infusions. Historically, amphotericin B was used
prophylactically to prevent fungal infections. New studies are test-
ing whether voriconazole is superior to other antifungal agents for
prevention and treatment of invasive fungal disease. By compari-
son, voriconazole has fewer side effects than amphotericin B, with
less nephrotoxicity which is advantageous in the transplant setting
with concomitant administration of cyclosporine or tacrolimus.
The use of voriconazole has been associated with a decrease in the
number of Aspergillus cases but a concomitant rise in less serious
infections with azole-resistant candida species. The purpose of this
abstract is to outline the nursing care associated with patients with
invasive fungal disease. Speciﬁc goals will be to describe the clinical
presentation of the patient with fungal disease as well as the
treatment options and associated side effects.
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INHALED PENTAMIDINE IN PEDIATRIC PATIENTS UNDERGOING HE-
MATOPOIETIC STEM CELL TRANSPLANTATION
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Pneumocystis carinii pneumonia (PCP) is a potentially life
threatening opportunistic infection that occurs in immunosup-
pressed patients. The drug of choice for the treatment and
prevention of this disease is trimethoprim-sulfamethoxazole
(TMP) but alternatives are often needed because of adverse
effects or treatment failure. Pentamidine is one alternative com-
monly used in patients undergoing hematopoietic stem cell
transplantation because, unlike TMP, it is not myelosuppres-
sive. Pentamidine has very low rate of absorption from the
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